Shreeji

What Shreeji does

Shreeji Imaging and Diagnostic Centre Private Limited is a Mumbai-headquartered, family-owned manufacturer and distributor of PET (Positron Emission Tomography) radiotracers in India. Founded in 1990 by Dr. Amit Maniar and Meera Maniar originally as a diagnostic imaging business, Shreeji entered medical cyclotron-based radiotracer production in 2007–2008 and is among the first commercial cyclotron operators in India. The company operates two cGMP-ready cyclotron facilities — in Nerul (Navi Mumbai) and IMT Manesar (Gurugram, Delhi NCR) — and produces five fluorine-18-based radiopharmaceuticals: 18F-FDG (workhorse oncology/cardiology/neurology tracer), 18F-PSMA (prostate cancer), 18F-FDOPA (Parkinson's disease and neuroendocrine tumors), 18F-FES (breast cancer theranostics), and 18F-NaF (bone imaging).

Shreeji's business model is B2B sale of short-lived radiotracers (F-18 half-life ~110 minutes) to 160+ hospitals and diagnostic centers across 55+ Indian cities, supplemented by export supply to PET-CT centers in Colombo, Sri Lanka (since 2011) and Kathmandu, Nepal (since 2015). Distribution requires complex logistics managed directly by the company using both road and air freight, with a claimed >99% supply performance over 300+ supply days per year for more than a decade. The company supplies 120,000+ patient doses annually and operates an integrated digital platform for patient management, dose delivery, regulatory reporting, and invoicing. Pricing is not publicly disclosed; quotes are likely customized by product, volume, and delivery parameters under transaction-based commercial terms.

The company remains founder-managed and bootstrapped with no disclosed external institutional investment, financing capital-intensive cyclotron growth through debt. Second-generation family members have joined operations — Dr. Kunal Maniar as Executive Director and Head of R&D since 2019, and Advit Maniar as Executive Director overseeing commercial, regulatory, and digital functions since 2018. The stated corporate ambition is to become a global leader in theranostics, indicating potential expansion from diagnostics into therapeutic radiopharmaceuticals.

Name

Shreeji

Legal name

Shreeji Imaging and Diagnostic Centre Private Limited

Website

https://shreejiimaging.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

1–10 employees

Short description

Shreeji is a Mumbai-based manufacturer of PET radiotracers operating two cyclotron facilities in India. It supplies five 18F-based radiopharmaceuticals (FDG, PSMA, FDOPA, FES, NaF) to 160+ hospitals and diagnostic centers across 55+ Indian cities and exports to Sri Lanka and Nepal.

Ownership category

akta.pro rank

Product category

PET Radiopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

akta.pro secondary industries

Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA), Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors) (HLAIAGAG), Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution) (HLAIAGAH)

Keywords

• PET radiotracer manufacturing
• Medical cyclotron operations
• Fluorine-18 radiopharmaceuticals
• PET imaging diagnostics supply
• Nuclear medicine production

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. PET Radiotracer Manufacturing and Distribution: Shreeji generates revenue through the manufacture and B2B sale/distribution of PET radiotracers (18F-FDG, 18F-PSMA, 18F-FDOPA, 18F-FES, 18F-NaF) to hospitals, diagnostic centers, and PET imaging facilities across India and select export markets. The business model is characterized by capital-intensive cyclotron infrastructure, recurring institutional订单 (hospitals/diagnostic centers order on a recurring basis), and complex logistics for delivery of short-lived radioisotopes. The company maintains two cyclotron facilities to ensure supply reliability and geographic coverage.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Shreeji manufactures and distributes fluorine-18 (18F) based PET radiopharmaceuticals — specifically 18F-FDG, 18F-PSMA, 18F-FDOPA, 18F-FES, and 18F-NaF — using medical cyclotrons at its two cGMP-ready production facilities in Navi Mumbai and Gurugram (Delhi NCR). The company supplies these short-lived radiotracers directly to hospitals, diagnostic centers, and PET-CT facilities across India (55+ cities) and selected international markets (Sri Lanka, Nepal), serving oncology, cardiology, neurology, and theranostics applications.

Product overview

Shreeji is a market leader in PET radiotracer manufacturing and distribution in India, offering a portfolio of five distinct fluorine-18 based radiopharmaceutical products. The core offering includes 18F-FDG as the primary workhorse tracer for oncology, cardiology, and neurology applications; 18F-PSMA (18F-JK-PSMA-7) for prostate cancer diagnostics; 18F-FDOPA for Parkinson's disease and neuroendocrine tumors; 18F-FES for breast cancer and estrogen receptor imaging; and 18F-NaF for bone imaging. The company operates strategically located cyclotron facilities in Mumbai (Navi Mumbai) and Delhi NCR (IMT Manesar, Gurugram) with cGMP-ready production capabilities, enabling reliable and timely delivery of short-lived PET radiotracers across India and select international markets.

Differentiator

Problem solved

Functional benefit

Products and services

• 18F-FDG (Fluorodeoxyglucose) The workhorse PET radiotracer with wide application in oncology (diagnosis, staging, recurrence detection), cardiology (myocardial viability assessment), and neurology (epileptogenic foci evaluation). Also used for infections and inflammatory disorders including fever of unknown origin, sarcoidosis, and inflammatory bowel disease. Sold to hospitals and diagnostic centers with PET-CT capabilities.
• 18F-PSMA (18F-JK-PSMA-7) Tracer of choice for prostate cancer detection, used for detecting prostate-specific membrane antigen (PSMA) expressing lesions in men with suspected metastatic prostate cancer who are candidates for initial definitive therapy and with suspected recurrence based on elevated serum PSA levels. Sold to hospitals and diagnostic centers.
• 18F-FDOPA (Fluorodopa) Tracer ideal for Parkinson's disease diagnosis (detecting loss of dopaminergic neuron terminals) and specific neuroendocrine tumors (NETs) including pheochromocytoma, paraganglioma, medullary thyroid cancer, and pancreatic beta-cell hyperplasia. Sold to hospitals and diagnostic centers.
• 18F-FES (Fluoroestradiol) Gateway for personalized therapy in breast cancer, used for detection of estrogen receptor (ER) expressing lesions in patients with recurrent or metastatic breast cancer and for detecting ER expression in tumors such as endometrial and ovarian cancers. Sold to hospitals and diagnostic centers.
• 18F-NaF (Sodium Fluoride) Gold standard for bone scans, used for detection and localization of bone metastases in adults, evaluation of back pain of ambiguous origin when conventional imaging is inconclusive, and detection of bone lesions related to suspected child abuse. Sold to hospitals and diagnostic centers.

Quantifiable outcome

• 120,000+ patient doses supplied annually
• +3 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• GE HealthcarecoreTechnology or Integration · 1 January 2007Shreeji collaborated with GE Healthcare to establish its medical cyclotron facilities. GE provided the cyclotron equipment and technical collaboration necessary for setting up the first commercial PET radiotracer production operation in India. Shreeji along with GE worked with government and airlines to secure necessary clearances for safe supply of FDG by flight, enabling air transport of short-lived radiotracers and opening up PET-CT markets across India.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Cardinal Health Nuclear Pharmacy Services: Operates the largest radiopharmacy network in the United States, distributing nuclear medicine products including PET tracers to hospitals and clinics — a comparable B2B radiopharmaceutical distribution model to Shreeji's cyclotron-to-hospital supply chain.
• Lantheus Holdings: Specialty radiopharmaceutical company with leading positions in diagnostic PET tracers (e.g., Pylarify for PSMA imaging) and other nuclear medicine products, directly competing in the same tracer categories as Shreeji.
• PETNET Solutions (Siemens Healthineers): Operates one of the largest global networks of cyclotron-based PET radiotracer manufacturing facilities, directly competing with Shreeji in the production and distribution of F-18 and other PET tracers to hospitals and imaging centers.
• Curium Pharma: Global manufacturer of radiopharmaceuticals including PET and SPECT tracers, directly comparable to Shreeji in product category (diagnostic radiopharmaceuticals) and B2B supply model to hospitals and imaging centers.

Emerging players

• Telix Pharmaceuticals: Emerging radiopharmaceutical company with growing PET imaging agent portfolio (including Illuccix for PSMA) that competes in the same oncology imaging categories as Shreeji, with growing geographic reach in Asia.

Broad incumbents

• Bracco Imaging: Global diagnostic imaging company with a portfolio that includes radiopharmaceuticals and contrast agents, offering overlapping capability with Shreeji in imaging agents and broader diagnostic products.
• Bayer (Radiology / Radiopharmaceuticals): Major pharmaceutical and imaging player with a radiopharmaceuticals franchise (historically Xofigo) and broader diagnostic imaging portfolio, representing an incumbent competitor with far greater capital and global reach.
• GE Healthcare: Manufactures and distributes PET radiotracers globally and is Shreeji's own technology partner for cyclotron equipment. Represents both an incumbent competitor and a strategic relationship for Shreeji's expansion.

Regional players

• Jubilant Pharmova: Indian pharmaceutical company with a radiopharmacy and contract manufacturing business that supplies radiopharmaceuticals in India, directly competing with Shreeji in the domestic PET tracer market.
• Board of Radiation and Isotope Technology (BRIT): Indian government entity under the Department of Atomic Energy that produces and supplies radioisotopes and radiopharmaceuticals domestically — the principal Indian state-owned counterpart to Shreeji in the radiotracer manufacturing space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/shreeji-imaging-and-diagnostic-centre-private-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shreeji